<DOC>
	<DOC>NCT00299130</DOC>
	<brief_summary>This study evaluated the efficacy and safety of rituximab in patients with active rheumatoid arthritis (RA).</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criteria: Adult patients 1880 years of age. Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis. Receiving outpatient treatment for RA. Swollen joint count (SJC) ≥ 8 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline. At screening, either Creactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour. Inadequate response to methotrexate, having received and tolerated at a dose of 1025 mg/week it for ≥ 12 weeks. Exclusion criteria: Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA. Inflammatory joint disease other than RA, or other systemic autoimmune disorder. Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16. Surgery within 12 weeks of study or planned within 24 weeks of randomization. Previous treatment with any approved or investigational biological agent for RA, an antialpha4integrin antibody or costimulation modulator, or celldepleting therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>RA</keyword>
	<keyword>Rituxan</keyword>
	<keyword>SERENE</keyword>
</DOC>